By Scientia Professor Gregory John Dore

Preprints

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks M; Law H; Danwilai T; Starr M; Munier ML; Christ D; Singh M; Croucher P; Brilot-Turville F; Turville S; Phan TG; Dore G; Darley D; Cunningham P; Matthews G; Kelleher A; Zaunders J, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947

Cysique L; Jakabek D; Bracken S; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Pires AS; Darley D; Byrne A; Phetsouphanh C; Kelleher A; Dore G; Matthews G; Guillemin G; Brew B, 2022, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study, http://dx.doi.org/10.1101/2022.06.07.22276020

Phetsouphanh C; Darley D; Wilson D; Howe A; Ling Munier M; Patel S; Juno J; Burrell L; Kent S; Dore G; Kelleher A; Matthews G, 2021, Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection, http://dx.doi.org/10.1101/2021.06.01.21257759

Darley DR; Dore GJ; Byrne A; Plit M; Brew BJ; Kelleher A; Matthews GV, 2021, Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort, http://dx.doi.org/10.1101/2021.03.29.21254211

Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffman M; Pöhlmann S; Dwyer DE; Rockett R; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2020, SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants, http://dx.doi.org/10.1101/2020.12.19.20248567

Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, http://dx.doi.org/10.2139/ssrn.3213670

Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916

Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Study Group REACT, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248

Lockhart I; Yeo MGH; Hajarizadeh B; Dore GJ; Danta M, Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis, http://dx.doi.org/10.2139/ssrn.3950271

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267510

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267527

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, http://dx.doi.org/10.2139/ssrn.3709824

Joseph S; Dore GJ, Vaccine Apartheid: A Human Rights Analysis of COVID-19 Vaccine Inequity, http://dx.doi.org/10.2139/ssrn.3876848

Other

Dore GJ; Grebely J, 2017, Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030, Elsevier, http://dx.doi.org/10.1016/j.jhep.2017.03.035

Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ, 2017, Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C, Elsevier, http://dx.doi.org/10.1016/j.jhep.2016.12.028

Back to profile page